Paris, Boston, and London, March 27, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the...
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio
read more
Search Results
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults
Cellvizio Food Intolerance Test (C-FIT) delivers real-time, in vivo visibility to accurately identify food intolerance in patients suffering from...
Mauna Kea Technologies Welcomes Benoit Chardon as Senior Advisor to Scale its Irritable Bowel Syndrome and Food Intolerance Business
Mr. Chardon is a recognized commercialization expert with a successful track record in new category creation in the health & wellness industry ...
Mauna Kea Technologies Announces Initiation of Coverage by EuroLand Corporate
Paris and Boston, February 1, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary...
Mauna Kea Technologies Reports Full Year 2023 Sales of €10.5m, Up +42% vs 2022
Record-high PPU Growth of +109%1 in Q4 2023, Full Year PPU Growth of +57%1 Tasly and Telix Partnerships Remain On-Track Partnership Pipeline...
Mauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic Surgery
Builds on existing research collaboration for precision surgery in urology Telix Pharmaceuticals to acquire a ~19% stake in Mauna Kea Technologies...
Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer
Ongoing enrollment of over 200 patients across 7 sites in Europe and the U.S. Paris and Boston, November 2, 2023 – 08:00 a.m. CET...
Mauna Kea Technologies Reports 74% Increase in 9-Month 2023 Sales
Strong performance thanks to partnership revenue and U.S. growth +40% increase in Q3 U.S. PPU revenue Strong convergence of current and upcoming...
Mauna Kea Technologies Announces the Publication of Positive Results of a Randomized Controlled Trial in the Field of Interstitial Lung Disease
Confocal Laser Endomicroscopy with Cellvizio proven superior to X-ray fluoroscopy for the guidance of transbronchial cryobiopsy, offering a...
Mauna Kea Technologies Reports H1 2023 Financial Results
Strong H1 sales growth (+101%) and significant reduction in current operating loss (-78%) Generated YTD net profit, supported by contribution...
Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone
Dr. Jeong Kim Uses Cellvizio to Improve Diagnosis of Gastric Disease Paris and Boston, September 19, 2023 – 8:00 a.m. CEST – Mauna Kea...
Mauna Kea Technologies Announces the Transfer of its Shares on the Euronext Growth Paris Market Will Be Effective August 8 2023
Paris and Boston, August 4, 2023 – 8:00 a.m. CEST – Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the...